FDA Brief

Warning letters Drugs

FDA warning letter to

EnviroServe Chemicals & Cleaners Ltd.

High riskIssued Sep 9, 2024Posted Sep 17, 2024Center for Drug Evaluation and Research (CDER)

EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

What happened

FDA reviewed records EnviroServe submitted after FDA's June 16, 2022 request for records about the Etobicoke facility. FDA found significant CGMP (current good manufacturing practice) violations, including missing ingredient identity and methanol testing, missing finished-product testing, inadequate stability data, and weak quality-unit oversight. FDA also found SOPURE Antiseptic Skin Cleanser was an unapproved new drug and misbranded (false or misleading labeling), including website statements suggesting FDA approval.

What FDA found

  1. EnviroServe did not test each incoming ingredient's identity or validate supplier test results, and did not test ethanol for methanol.

    21 CFR 211.84(d)(1) & 211.84(d)(2)
  2. Batch records lacked adequate finished-product tests for active ingredient identity and strength and for impurities before release.

    21 CFR 211.165(a)
  3. Stability data did not adequately test identity and strength to support the labeled expiry date.

    21 CFR 211.166(a)
  4. The quality unit did not effectively oversee manufacturing quality and approve or reject materials and products.

    21 CFR 211.22(a)
  5. SOPURE was an unapproved new drug because it was not generally recognized as safe and effective and did not meet the OTC rules for marketing without an approved application.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)
  6. SOPURE was misbranded because the website suggested FDA approval and the Drug Facts panel included extra language and the product did not meet section 505G requirements.

    sections 502(a), 502(c), and 502(ee) of the FD&C Act, 21 U.S.C. 352(a), 352(c), 352(ee); 21 CFR 207.77(a), 201.66(d)(7)

What FDA wants

FDA tells EnviroServe to correct the violations promptly and respond in writing within 15 working days, specifying what it has done and how it will prevent recurrence; if it cannot finish, it must explain the delay and give a schedule. FDA also recommends a qualified CGMP consultant before resuming drug manufacturing for the U.S. market.

Who should pay attention

  • brands that buy or private-label hand sanitizer from this contract manufacturer
  • retailers and distributors sourcing OTC antiseptic products from Canada
  • quality teams managing supplier qualification and import alerts

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk